Are too many people being given GLP-1 medicines?
GLP-1 medicines are real treatments for obesity and diabetes, not a wellness upgrade for anyone who wants to drop a few kilos. The honest question is whether they fit your body and your health, not whether they are popular right now.
You have seen the news. Friends talk about it. Ads pop up on your phone. GLP-1 medicines like semaglutide and tirzepatide are everywhere. So a fair question pops up: are doctors giving these medicines to too many people, or for the wrong reasons? The honest answer is mixed. These are real, helpful medicines for people who truly need them. But they are not meant for everyone who wants to lose a little weight. Let us look at who they are really for.
Who is this medicine actually for?
The medicine labels are clear about who qualifies. The US FDA label for Wegovy (semaglutide) says it is for adults and children aged 12 and older with obesity, or adults with overweight plus at least one weight-related condition. The Zepbound (tirzepatide) label says the same thing in plain numbers: BMI of 30 or more, or BMI of 27 to less than 30 with a condition like diabetes, high blood pressure, or sleep apnea. So the label itself draws a line. It is not for someone with a small cosmetic weight goal. In India, the drug regulator has drawn its own line. The CDSCO expert committee said the new GLP-1 tablet orforglipron should be sold only on prescription from endocrinologists or internal-medicine specialists. That means a qualified specialist, not a casual wellness clinic, decides who gets it.
Appropriate use vs casual use
Anyone who wants to lose weight should be on a GLP-1 medicine.
mostly falseMostly false. These medicines are for adults with obesity, or overweight plus a weight-related condition, taken with diet and activity. The WHO guideline says GLP-1 therapies may be used as long-term treatment in adults living with obesity. They are not a general wellness tool for cosmetic weight loss. There is a real demand surge behind this worry: one US study found patients without diabetes starting GLP-1 treatment rose from about 21,000 in 2019 to over 174,000 in 2023, an increase of more than 700%. That kind of jump is why doctors worry the medicine could crowd out people with genuine medical need, such as diabetes or severe obesity.
How to have an honest talk with your doctor
The bottom line
GLP-1 medicines are real medicine for a defined medical need, not a wellness upgrade for everyone. The labels say who they are for, the WHO says they belong with adults living with obesity, and India wants a specialist to decide. If you truly qualify, they can be life-changing. If you do not, the side effects, cost, and lifelong trade-off are not worth it. Talk to a qualified doctor, not an ad.